[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Medical Centre Ljubljana\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":722},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,51,0,25,[9,51,87,118,148,183,211,237,259,287,323,354,376,409,440,465,486,503,531,549,579,605,630,663,691],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652160","biological-profile-of-primary-and-secondary-lymphedema-inflammatory-endothelial-metabolic-lymphatic-and-fibrotic-markers-100652160",false,"NCT07770399","Biological Profile of Primary and Secondary Lymphedema: Inflammatory, Endothelial, Metabolic, Lymphatic, and Fibrotic Markers","LYMPH5","General inclusion criteria for all participants:\n\n* Adults aged 18 to 45 years.\n* Ability to understand the study information and provide written informed consent.\n* Willingness and ability to attend one study visit and undergo the planned clinical assessment, blood sampling, and skin swab collection.\n\nAdditional inclusion criteria for participants with primary lymphedema:\n\n* Clinically and, where appropriate, imaging-confirmed primary lymphedema of an upper or lower extremity.\n* Lymphedema classified as Stage I or II according to the applicable clinical classification. Participants with Stage III disease may be included if disease progression is associated with recurrent cellulitis or erysipelas and this is documented separately.\n* Current treatment or follow-up at the Department of Dermatovenereology, University Medical Centre Ljubljana.\n\nAdditional inclusion criteria for participants with secondary lymphedema:\n\n* Clearly established acquired cause of lymphedema.\n* Comparable anatomical location and, where feasible, disease stage to the primary lymphedema group.\n* Completion of active oncological treatment, where secondary lymphedema is cancer-related.\n\nHealthy control participants:\n\n* No clinical signs or previous history of lymphedema.\n* Comparable age and sex distribution to the lymphedema groups.\n\nExclusion Criteria\n\n* Other major causes of limb swelling, including heart failure, nephrotic syndrome, clinically significant thyroid disease, or medications likely to cause edema when the effect cannot be adequately accounted for.\n* Acute systemic infection or cellulitis\u002Ferysipelas within 4 weeks before study enrollment.\n* Pregnancy or breastfeeding.\n* Active oncological treatment.\n* Active smoking.\n* Active inflammatory skin disease that could substantially affect the skin microbiome or systemic inflammatory biomarkers.\n* Clinically manifest cardiovascular disease or previous cardiovascular event.\n* Treatment with medications that are expected to substantially affect the selected immunological or metabolic outcomes when their effects cannot be adequately accounted for in the analysis.\n* Inability to provide valid informed consent.\n\nGender eligibility:\n\n\\- Eligibility is not restricted by gender identity. Biological sex will be recorded where relevant for clinical and laboratory analyses, including sex-specific calculation of selected metabolic indices.\n\nWithdrawal:\n\nParticipants may withdraw from the study at any time without providing a reason and without any effect on their subsequent medical care.",true,"ALL","18 Years","35 Years",{"count":22,"type":23},90,"ESTIMATED","OBSERVATIONAL","This observational, cross-sectional study aims to characterize the biological profile of primary and secondary lymphedema by investigating five interconnected biological domains: T helper 2 (Th2)-related inflammation, endothelial activation, metabolic dysfunction, lymphatic biology, and tissue fibrosis.\n\nLymphedema is traditionally considered a disorder of impaired lymphatic drainage resulting in the accumulation of interstitial fluid. However, increasing evidence suggests that its development and progression involve chronic inflammation, endothelial dysfunction, metabolic alterations, abnormal lymphatic signaling, adipose tissue accumulation, and progressive tissue fibrosis. While these mechanisms have been investigated predominantly in secondary lymphedema, the systemic biological profile of primary lymphedema remains insufficiently characterized.\n\nThe study will include approximately 90 participants aged 18-45 years: 30 participants with primary lymphedema, 30 participants with secondary lymphedema, and 30 healthy control participants matched by age and sex. Each participant will attend one study visit lasting approximately 45-60 minutes.\n\nClinical assessment will include medical history, demographic characteristics, blood pressure, body measurements, assessment of lymphedema location and clinical stage, pitting edema, Stemmer sign, skin changes, limb volume measurement by perometry, and assessment of tissue firmness. Venous blood samples will be collected to assess routine laboratory parameters and a panel of inflammatory, endothelial, metabolic, lymphatic, and fibrotic biomarkers. A standardized skin swab will also be collected for exploratory skin microbiome analysis.\n\nFor the primary analysis, one representative marker will be selected in advance for each of the five biological domains: interleukin-13 (IL-13) for Th2-related inflammatory activity, soluble vascular cell adhesion molecule-1 (sVCAM-1) for endothelial activation, homeostatic model assessment of insulin resistance (HOMA-IR) for metabolic dysfunction, vascular endothelial growth factor C (VEGF-C) for lymphatic biology, and transforming growth factor beta 1 (TGF-β1) for tissue fibrosis. These five variables will constitute the co-primary outcome measures.\n\nSecondary analyses will evaluate additional biomarkers within each biological domain and their associations with clinical severity, including lymphedema stage, limb volume, pitting edema, Stemmer sign, and skin fibrosis. The study will also investigate relationships between the different biological domains and assess differences between primary and secondary lymphedema.\n\nExploratory analyses will characterize the skin microbiome of affected and standardized comparison sites and investigate associations between microbiome composition, clinical disease characteristics, and systemic biomarkers. In participants with primary lymphedema without a previously established genetic diagnosis, selected genetic variants associated with primary lymphedema will also be investigated.\n\nThe study will provide a comprehensive assessment of biological alterations associated with lymphedema and may help clarify differences between primary and secondary disease. The findings may contribute to a better understanding of lymphedema as a complex biological and tissue disorder and provide a basis for future studies of more targeted diagnostic and therapeutic approaches.",[27,28],"Primary Lymphedema","Secondary Lymphedema",[30,31,32,33,34,35,36,37],"lymphedema","primary lymphedema","secondary lymphedema","inflammation","endothelial activation","metabolic dysfunction","tissue fibrosis","skin microbioma","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-20","ACTUAL",{"date":44,"type":23},"2026-09",{"date":46,"type":23},"2028-10",{"name":48,"class":49},"University Medical Centre Ljubljana","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100652393","mitochondrial-intervention-for-resilience-in-older-adults-with-coenzyme-q10-100652393","NCT07772336","MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10","Mitochondrial Intervention for Resilience in Older Adults With Coenzyme Q10","MIRO-Q","Inclusion Criteria\n\n* Age 65 years or older.\n* Community-dwelling older adult.\n* Presence of signs of reduced biological resilience or prefrailty, defined by meeting at least one of the following criteria:\n\n  * Prefrailty according to the Fried frailty phenotype, defined as the presence of 1-2 of the following criteria: unintentional weight loss, self-reported exhaustion, reduced physical activity, slow walking speed, or reduced handgrip strength; or\n  * Reduced physical performance, defined as a Short Physical Performance Battery (SPPB) score of ≤9; or\n  * Increased functional vulnerability, defined as a Clinical Frailty Scale (CFS) score of ≥4.\n* Ability to understand the study procedures and comply with the study protocol.\n* Ability and willingness to provide written informed consent before participation.\n\nExclusion Criteria\n\n* Established frailty with severe functional impairment that would interfere with study participation or outcome assessment.\n* Advanced dementia or cognitive impairment preventing informed consent or reliable participation in study assessments.\n* Active malignant disease or ongoing cancer treatment.\n* Acute inflammatory disease or acute infection at the time of enrollment.\n* Acute or unstable medical condition that could substantially affect functional performance, cognitive assessment, or the safety of the intervention.\n* Any medical condition considered by the investigator to make participation inappropriate or unsafe.\n* Current use of CoQ10 supplementation at a dose that could interfere with assessment of the study intervention, unless discontinued for the predefined washout period.\n* Known hypersensitivity or intolerance to CoQ10 or any component of the study product.\n* Participation in another interventional clinical trial that could affect the outcomes of the present study.","65 Years",{"count":61,"type":23},100,"INTERVENTIONAL",[64],"NA","This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty.\n\nParticipants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging.\n\nThe study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging.\n\nThe study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.",[67,68,69,70,71],"Frailty","Aging","Mitochondria Health","Skin Aging","Mitochondrial Dysfunction",[73,74,75,76,77,78,79],"frailty","aging","older adults","Coenzyme Q10","mitochondrial dysfunction","geroscience","functional aging","2026-08-13",{"date":82,"type":42},"2026-08-19",{"date":44,"type":23},{"date":85,"type":23},"2027-02",{"name":48,"class":49},{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":62,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100652257","effects-of-exercise-in-patients-with-repaired-coarctation-of-the-aorta-100652257","NCT07771023","Effects of Exercise in Patients With Repaired Coarctation of the Aorta","Effects of Exercise on Select Indicators of Cardiovascular Health in Patients With Repaired Coarctation of the Aorta","KOREKT","Inclusion Criteria:\n\n* surgically repaired coarctation of the aorta,\n* age at least 18 years, and\n* signed informed consent form.\n\nExclusion Criteria:\n\n* residual aortic stenosis (gradient across the narrowing \\>20 mmHg),\n* presence of ascending aortic aneurysm,\n* recent major cardiovascular event or other event requiring hospitalization (event less than 2 months before inclusion),\n* unstable rhythm disturbances,\n* unstable or low-threshold angina pectoris,\n* NYHA class III or IV heart failure, and\n* pregnancy.",{"count":96,"type":23},45,[64],"This interventional study will investigate the effects of high-intensity interval training (HIIT) in adults with repaired coarctation of the aorta. Participants will be randomised into three groups: HIIT performed at home, HIIT performed in a supervised outpatient setting, or a control group receiving usual care. The two HIIT protocols will be identical in intensity and progression, individually prescribed for each patient.\n\nThe study will evaluate the effects of HIIT on exercise capacity, health-related quality of life, blood pressure response to exercise, and other select measures of cardiovascular health, including vascular stiffness and endothelial function. In addition, the study will examine the acute effects of a single exercise session on arterial stiffness.",[100,101],"Coarctation of the Aorta","Coarctation of Aorta",[103,104,105,106,107,108,109,110],"exercise","HIIT","home-based exercise","exercise training","cardiopulmonary exercise testing","arterial stiffness","hypertensive reaction","congenital heart disease",{"date":39,"type":42},{"date":113,"type":23},"2026-08",{"date":115,"type":23},"2027-10",{"name":48,"class":49},2,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":125,"minAge":19,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":62,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":50},"100652193","phase-4-the-effect-of-empagliflozin-and-metformin-on-oxidative-capacity-and-microvascular-reactivity-of-skeletal-muscle-in-patients-with-type-2-diabetes-mellitus-100652193","NCT07771010","The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus","EMPOWER","Inclusion Criteria:\n\n* Male sex\n* Age 18-75 years\n* Newly diagnosed type 2 diabetes mellitus, confirmed no more than 2 years prior to enrollment\n* Body mass index (BMI) 25-35 kg\u002Fm²\n* Currently managed at a diabetes outpatient clinic\n* No known chronic diabetes-related complications\n* No prior antidiabetic pharmacological treatment, with the exception of sulfonylureas\n\nExclusion Criteria:\n\n* Other forms of diabetes mellitus (i.e., not type 2)\n* Type 2 diabetes mellitus known for more than 2 years\n* Comorbidities known to independently affect skeletal muscle oxidative capacity, including: spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cystic fibrosis, local joint immobility, or hemiplegia\n* Known mitochondrial disease\n* Heart failure, NYHA class II or higher\n* Chronic kidney disease, stage 3 or higher\n* Poorly controlled chronic medical conditions (e.g., arterial hypertension, hypothyroidism)\n* Recurrent urinary tract infections\n* Active malignancy currently undergoing oncologic treatment\n* Life expectancy less than 3 months\n* Symptomatic hyperglycemia with fasting plasma glucose above 18 mmol\u002FL, HbA1c ≥ 10%\n* Unwillingness to provide informed consent","MALE","75 Years",{"count":128,"type":23},54,[130],"PHASE4","The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2 diabetes. As the primary outcome, the investigators selected the change in skeletal muscle oxidative capacity and posed the following scientific question: Does empagliflozin significantly improve the oxidative capacity of skeletal muscle? The study will enroll 54 individuals with type 2 diabetes in a prospective, randomized, interventional, open-label study. Participants will be randomized into 3 equally sized groups: 1) a group receiving empagliflozin; 2) a group receiving metformin; and 3) a group receiving a combination of both drugs (empagliflozin and metformin). The investigators will analyze the clinical variables of the subjects, near-infrared spectroscopy (NIRS) measurements over the flexor digitorum superficialis muscle of the non-dominant arm at rest, after submaximal muscular work, and during transient brachial artery occlusion at specified time intervals (14 days, 1 month, 3 months, 6 months), as well as body composition, physical performance, and glycemic control following the pharmacological intervention.",[133],"Diabetes Type 2",[135,136,137,138,139,140],"type 2 diabetes mellitus","Empagliflozin","Metformin","Skeletal muscle oxidative capacity","Near-infrared spectroscopy","Microvascular reactivity","RECRUITING",{"date":39,"type":42},{"date":144,"type":42},"2026-04-16",{"date":146,"type":23},"2028-07-31",{"name":48,"class":49},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":156,"minAge":19,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":62,"phases":160,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":50},"100650401","posh-ex-physiotherapist-led-telerehabilitation-exercise-programme-for-postpartum-sexual-health-100650401","NCT07747285","POSH-Ex: Physiotherapist-Led Telerehabilitation Exercise Programme for Postpartum Sexual Health","POSH-Ex: Randomized Controlled Trial Evaluating a Standardized Physiotherapist-Led Telerehabilitation Programme for Postpartum Sexual Health","POSH-Ex","Inclusion Criteria:\n\n* Women aged 18 to 45 years.\n* Between 10 and 12 weeks postpartum at the time of enrolment.\n* Singleton live birth.\n* Ability to understand and communicate in the Croatian language.\n* Ability to participate safely in moderate-intensity exercise.\n* Access to a computer, tablet, or smartphone with a stable internet connection for participation in online exercise sessions.\n* Willingness to comply with the study protocol and attend supervised exercise sessions.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* • Medical contraindications to exercise according to current clinical recommendations.\n\n  * Pregnancy during the study period.\n  * Severe musculoskeletal, neurological, cardiovascular, or other medical conditions preventing safe participation in exercise.\n  * Current participation in another structured postpartum rehabilitation or exercise programme.\n  * Severe psychiatric disorder requiring immediate specialist treatment.\n  * Positive response to Item 10 of the Edinburgh Postnatal Depression Scale indicating current thoughts of self-harm. Such participants will be referred for appropriate clinical assessment before potential study participation.\n  * Inability to complete study questionnaires or follow study procedures.","FEMALE","45 Years",{"count":159,"type":23},84,[64],"Postpartum women frequently experience impairments in sexual function, pelvic floor dysfunction, fatigue, and depressive symptoms, all of which may adversely affect their quality of life during the postpartum period. Although pelvic floor muscle training is recommended as part of postpartum rehabilitation, evidence regarding comprehensive physiotherapist-led exercise programmes specifically targeting postpartum sexual health remains limited. Furthermore, no standardized telerehabilitation programme has yet been evaluated using a randomized controlled trial design.\n\nThe aim of this randomized controlled trial is to evaluate the effectiveness of the POSH-Ex (Postpartum Sexual Health Exercise) programme, a standardized 12-week physiotherapist-led telerehabilitation intervention designed to improve female sexual function and overall postpartum health after childbirth. Secondary objectives are to evaluate its effects on pelvic floor muscle strength, physical activity, fatigue, depressive symptoms, health-related quality of life, and body composition.\n\nA total of 84 postpartum women will be randomly allocated in a 1:1 ratio to either the intervention group or the control group. Participants in the intervention group will complete supervised online exercise sessions twice weekly for 12 weeks, while participants in the control group will receive usual postpartum care. Outcome assessments will be performed at baseline and immediately after completion of the intervention.\n\nThe primary outcome is female sexual function assessed using the Female Sexual Function Index (FSFI). Secondary outcomes include pelvic floor muscle strength, physical activity, fatigue, depressive symptoms, health-related quality of life, and body composition. The findings are expected to provide high-quality evidence regarding the effectiveness of a standardized telerehabilitation programme for postpartum rehabilitation and may contribute to the development of evidence-based postpartum rehabilitation programmes and future clinical practice guidelines.",[163,164,165,166],"Postpartum Sexual Dysfunction","Postpartum Depression","Fatigue","Physical Activity",[168,169,170,171,172,173,174,154],"postpartum","Postpartum rehabilitation","Postpartum sexual health","Female sexual function","Pelvic floor muscle training","Telerehabilitation","Exercise","2026-07-30",{"date":177,"type":42},"2026-08-05",{"date":179,"type":23},"2026-09-01",{"date":181,"type":23},"2027-09-30",{"name":48,"class":49},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":62,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":50},"100648528","assessment-of-catheter-tissue-contact-in-pfa-100648528","NCT07721948","Assessment of Catheter Tissue Contact in PFA","Assessment of Electrode-tissue Contact and Pulmonary Vein Isolation Durability After Pulsed Field Ablation With a Circular \"Single Shot\" Catheter in Patients With Paroxysmal Atrial Fibrillation","ASSESS PFA","Inclusion Criteria:\n\n* Patients with electrocardiographically documented paroxysmal atrial fibrillation (AF), defined according to the European Heart Rhythm Association (EHRA) guidelines\n\nExclusion Criteria:\n\n* Contraindication to pulsed field ablation in the left atrium (e.g., presence of a left atrial appendage occlusion device).\n* Contraindication to undergoing the procedure under general anesthesia.\n* Age \\>80 years.\n* Markedly enlarged left atrium (diameter \\>50 mm on echocardiography, LAVI \\>50 mL\u002Fm²).\n* Life expectancy \\\u003C1 year.\n* Acute life-threatening illness.\n* Presence of left atrial thrombus.\n* Secondary atrial fibrillation.\n* Previous left atrial ablation.","80 Years",{"count":193,"type":23},60,[64],"Pulmonary vein isolation remains the cornerstone of invasive treatment for atrial fibrlllation. Despite recent technological advances in the field of pulsed field ablation (PFA) pulmonary vein isolation durability and arrhythmia free success rates remain approximately at the level of previous years and the radiofrequency ablation era.\n\nIsolation durability during PFA procedures might be enhanced by:\n\n1. Intraprocedural monitoring contact of catheter electrode to atrial tissue.\n2. Intraprocedural assessment of the transmurality of irreversible electroporation lesion.\n\nThe aim of our study is to use intracardiac electrogram (iEGM) based analysis for assessment of catheter-tissue contact and PFA lesion durability.",[197],"Atrial Fibrillation (AF)",[199,200,201,202,203],"Atrial Fibrillation","Pulsed field ablation","Intracardiac electrogram","Pulse Select","Contact assessment","2026-07-18",{"date":206,"type":42},"2026-07-23",{"date":179,"type":23},{"date":209,"type":23},"2028-09-01",{"name":48,"class":49},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":50},"100644103","prediction-of-pancreatogenic-diabetes-after-partial-resection-of-the-pancreas-100644103","NCT07665710","Prediction of Pancreatogenic Diabetes After Partial Resection of the Pancreas","Inclusion Criteria:\n\n* age ≥ 18 years\n* planned partial resection of the pancreas\n* absence of known diabetes before the procedure\n* absence of known borderline basal glycemia before the procedure\n* absence of impaired glucose tolerance before the procedure\n* signed written informed consent\n\nExclusion Criteria:\n\n* known diabetes mellitus before the procedure\n* known borderline basal glycemia before the procedure\n* impaired glucose tolerance before the procedure\n* inability to provide informed consent\n* withdrawal of consent during the course of the study\n* total resection of the pancreas\n* a subsequent decision for conservative treatment (based on clinical characteristics at the time of the surgical procedure)",{"count":218,"type":23},150,"The primary aim of the study is to identify clinical, laboratory, imaging, and pathohistological risk factors for the development of pancreatogenic diabetes after partial resection of the pancreas (PRP) and, based on these, to build a predictive model that would enable reliable and accurate identification of patients who will develop pancreatogenic diabetes. A review of the literature shows that there is currently no validated tool available in clinical practice for identifying patients at risk of this type of diabetes after PRP. Etiological differences between type 2 diabetes and pancreatogenic diabetes often lead to late diagnosis, limiting opportunities for timely intervention. The development of a comprehensive predictive model would contribute to a better understanding of the pathophysiology of pancreatogenic diabetes, enable the identification of patients at risk, facilitate tailored clinical monitoring, and allow the implementation of targeted preventive or therapeutic measures in the perioperative period.\n\nBased on a review of the literature and clinical observations, the investigators formulated the following hypotheses:\n\nH1: Clinical, laboratory, imaging, and pathohistological variables are independently associated with the development of pancreatogenic diabetes after partial pancreatic resection.\n\nH2: A predictive model that allows reliable and accurate identification of patients who will develop pancreatogenic diabetes can be build based on the identified variables (H1).\n\nH3: A comprehensive predictive model in the perioperative period allows more precise identification of patients who will develop pancreatogenic diabetes, and thus more effective risk stratification compared to the use of individual risk factors (variables).\n\nBased on the reviewed literature and our own clinical observations, this constitutes an original contribution to science. The investigators expect that the research will identify key clinical, laboratory, imaging, and pathohistological factors associated with the development of pancreatogenic diabetes after partial pancreatic resection. The development of a clinically useful predictive model that will allow individual risk assessment for the development of pancreatogenic diabetes in patients after partial pancreatic resection is anticipated. A similar comprehensive model has not yet been described in the accessible literature. The research will contribute to a better understanding of metabolic changes and will enable the identification of patients who will develop pancreatogenic diabetes after partial pancreatic resection. The results of the study could provide a basis for improved perioperative monitoring of these patients in the field of pancreatogenic diabetes.",[221],"Pancreatogenic Diabetes Mellitus",[223,224,225,226,227,228],"Partial Pancreatectomy","Pancreatogenic Diabetes","Prediction Model","Pancreas Volume","C-peptide","HOMA-IR","2026-07-14",{"date":231,"type":42},"2026-07-16",{"date":233,"type":42},"2026-04-01",{"date":235,"type":23},"2029-04-01",{"name":48,"class":49},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":62,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":50},"100645500","phase-4-hydrocortisone-versus-methylprednisolone-for-the-treatment-of-glucocorticoid-induced-adrenal-insufficiency-100645500","NCT07703098","Hydrocortisone Versus Methylprednisolone for the Treatment of Glucocorticoid-Induced Adrenal Insufficiency","Inclusion Criteria:\n\n* Age over 18 years.\n* Suspected adrenal insufficiency due to receiving supraphysiological doses of methylprednisolone for more than 4 weeks.\n* Receiving methylprednisolone 4 mg for at least the last 4 weeks.\n* Morning cortisol lower than 300 nmol\u002FL.\n* Inadequate result of a short ACTH test performed on a physiological dose of methylprednisolone (cortisol rise after 30 min under 470 nmol\u002FL AND after 60 min under 500 nmol\u002FL).\n* No further indication for treating the underlying disease, and retreatment with glucocorticoids is not expected in the next 2 years.\n* Consent to participate in the research.\n\nExclusion Criteria:\n\n* Known organic disease of the pituitary-adrenal axis.\n* Body mass over 130 kg.\n* Advanced comorbidities.\n* Advanced heart failure (NYHA IV).\n* Chronic kidney disease IV, eGFR under 30 ml\u002Fmin.\n* Liver cirrhosis.\n* Active malignant disease.\n* Immune deficiencies.\n* Planned major surgery during the study duration.\n* Receiving drugs affecting cortisol metabolism or interfering with cortisol measurements (e.g., systemic estrogens, strong inducers or inhibitors of CYP3A4).\n* Conditions affecting cortisol metabolism (pregnancy, liver disease, nephrotic syndrome).\n* Alcohol dependence syndrome (consuming more than 21 units of alcohol per week).\n* Shift (night) work.\n* Presence of comorbidities with an expected life expectancy of less than 3 years.",{"count":244,"type":23},66,[130],"This study aims to compare the use of methylprednisolone and hydrocortisone as replacement therapies in patients with glucocorticoid-induced adrenal insufficiency.\n\nThe primary goal is to evaluate and compare the recovery of the hypothalamic-pituitary-adrenal (HPA) axis.",[248],"Adrenal Insufficiency",[250,251,252],"hydrocortisone","Glucocorticoid-Induced Adrenal Insufficiency","methylprednisolone","2026-07-08",{"date":229,"type":42},{"date":179,"type":23},{"date":257,"type":23},"2030-09-01",{"name":48,"class":49},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":62,"phases":268,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":50},"100637372","phase-4-dual-pcsk9-inhibition-with-inclisiran-and-alirocumab-in-secondary-prevention-100637372","NCT07581808","Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention","PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary Prevention","PCSK9-DUO","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Established atherosclerotic cardiovascular disease (secondary prevention), defined as prior cardiovascular events or imaging-confirmed atherosclerosis (e.g., coronary artery disease on angiography or CT, carotid plaque on ultrasound, or peripheral arterial disease).\n* Eligible for PCSK9 inhibitor therapy according to national clinical criteria\n* Fasting LDL cholesterol ≥2.5 mmol\u002FL and ≤5.0 mmol\u002FL at screening\n* Documented statin intolerance or contraindication to statin therapy\n* On stable background lipid-lowering therapy (including ezetimibe if applicable) for at least 4 weeks prior to enrollment\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Eligibility for PCSK9 inhibitor therapy solely based on elevated lipoprotein(a) \\>1000 mg\u002FL with LDL-C below inclusion threshold\n* Prior use of any PCSK9 inhibitor (alirocumab, evolocumab or inclisiran) before enrollment\n* Planned initiation or modification of lipid-lowering therapy during the study period\n* Known homozygous familial hypercholesterolemia\n* Active liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3× upper limit of normal\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Active malignancy or life expectancy \\\u003C1 year\n* Pregnancy, breastfeeding, or women of childbearing potential not using effective contraception\n* Known hypersensitivity to inclisiran, alirocumab, or any of their excipients\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n* Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results",{"count":193,"type":23},[130],"This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.\n\nLowering low-density lipoprotein cholesterol (LDL-C) is essential to reduce the risk of cardiovascular events. While PCSK9 inhibitors are effective, many patients treated with a single agent do not reach recommended LDL-C targets, especially those who cannot take statins.\n\nInclisiran and alirocumab reduce LDL-C through different mechanisms. Inclisiran decreases the production of PCSK9 in the liver, while alirocumab binds circulating PCSK9 in the blood. Combining these therapies may lead to a greater reduction in LDL-C levels.\n\nIn this randomized, open-label clinical trial, approximately 60 patients in secondary prevention will be assigned to one of three groups: inclisiran alone, alirocumab alone, or a combination of both treatments. Patients will be followed for 9 months with regular clinical and laboratory assessments.\n\nThe main goal of the study is to determine whether combination therapy leads to greater LDL-C reduction compared to each treatment alone. Secondary objectives include assessing the proportion of patients achieving target LDL-C levels and evaluating treatment safety and tolerability.",[271,272],"Hypercholesterolemia","Atherosclerotic Cardiovascular Disease (ASCVD)",[274,275,276,277,278],"Alirocumab","Inclisiran","LDL cholesterol","Secondary prevention","Statin intolerance","2026-05-28",{"date":281,"type":42},"2026-06-02",{"date":283,"type":42},"2026-05-18",{"date":285,"type":23},"2027-06",{"name":48,"class":49},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":62,"phases":297,"briefSummary":298,"conditions":299,"keywords":304,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":50},"100639360","comparison-of-citrate-and-heparin-anticoagulation-during-postdilution-hemodiafiltration-100639360","NCT07618858","Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration","Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial","CITRA-HDF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End-stage kidney disease requiring maintenance postdilution hemodiafiltration\n* Stable chronic hemodialysis treatment three times weekly\n* Functional arteriovenous fistula\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation therapy\n* Dual antiplatelet therapy\n* Significant coagulopathy\n* Active bleeding\n* Acute kidney injury",{"count":296,"type":23},20,[64],"This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.\n\nThe primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).\n\nSecondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.\n\nTwenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.\n\nThe study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.",[300,301,302,303],"End-Stage Kidney Disease","Hemodiafiltration","Chronic Hemodialysis","Renal Failure",[305,306,301,307,308,309,310,311,312,313,314],"Citrate anticoagulation","Heparin anticoagulation","Dialysis","Biocompatibility","Beta-2 microglobulin","Complement activation","Regional citrate anticoagulation","Chronic dialysis","Thrombin-antithrombin complex","Platelet factor 4","2026-05-27",{"date":317,"type":42},"2026-06-01",{"date":319,"type":23},"2026-06-05",{"date":321,"type":23},"2027-04-01",{"name":48,"class":49},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":333,"conditions":334,"keywords":340,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":50},"100639718","the-role-of-cd34-stem-cells-in-the-pathogenesis-of-takotsubo-syndrome-100639718","NCT07604467","The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome","Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome","STRESS","Inclusion Criteria:\n\n* Minimum age 18 years\n* Established TTS per InterTak registry criteria\n* Signed consent form\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Ischemic heart disease with at least one complete total occlusion\n* Other concurrent cardiomyopathies\n* Active infectious myocarditis\n* obstructive coronary artery disease\n* Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event\n* Previous interventional coronary artery procedure in the last 6 months before TTS acute event\n* Significant valvular heart disease\n* Significant peripheral artery occlusive disease\n* Active or remitted hematologic malignancy\n* Patients receiving immunosuppressive therapy\n* Significant comorbiditeis affecting patients survival (malignancy)\n* Failure to obtain freely given, informed consent form.",{"count":332,"type":23},40,"The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.",[335,336,337,338,339],"Tako Tsubo Cardiomyopathy","Microvascular Dysfunction","CD34+ Stem Cells","Heart Failure","Cardiac Contractility Recovery",[341,342,343,344,345],"Takotsubo syndrome","CD34+ stem cells","heart failure","microvascular dysfunction","cardiac contractility recovery","2026-05-17",{"date":348,"type":42},"2026-05-22",{"date":350,"type":42},"2021-09-06",{"date":352,"type":23},"2026-12-31",{"name":48,"class":49},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":62,"phases":363,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":50},"100638089","phase-3-dexamethasone-in-tick-borne-encephalitis-100638089","NCT07584525","Dexamethasone in Tick-borne Encephalitis","Treatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical Trial","Inclusion Criteria:\n\n* age 18 years or older and\n* clinical signs and symptoms of meningoencephalitis or meningomyelitis and\n* cerebrospinal pleocytosis and\n* serological confirfmation of tick-borne encephalitis virus infection\n\nExclusion Criteria:\n\n* pregnancy or\n* severe neurological impairment befor tick-borne encephalitis or\n* systemic corticosteroid treatment in the past 30 days or\n* allergy to corticosteroids or\n* immunosuppresive condition or therapy such as HIV with CD4 \\\u003C 200\u002Fml, organ or bone marrow transplant, receiving chemotherapy, radiotherapy or any other immunosuppresive therapy, primary immunodeficiency, hematological maliganncy or\n* ventricular shunt or\n* endoscopically documented peptic gastric ulcer in the past six months or gastrointestinal bleeding with hemoglobin drop ≥ 20 units or\n* uncontrolled diabetes with hyperglicemia or\n* antiviral therapy with rilpivirin",{"count":362,"type":23},200,[364],"PHASE3","The purpose of this study is to investigate the efficacy of dexamethasone in patients with tick-borne encephalitis.",[367],"Tick-Borne Encephalitis","2026-05-07",{"date":370,"type":42},"2026-05-13",{"date":372,"type":42},"2024-05-03",{"date":374,"type":23},"2030-09-30",{"name":48,"class":49},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":62,"phases":386,"briefSummary":387,"conditions":388,"keywords":390,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":50},"100563260","phase-4-effect-of-early-combination-antihyperglycemic-treatment-on-metabolic-control-in-individuals-with-type-2-diabetes-100563260","NCT06613854","Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes","Effect of Early Combination Antihyperglycemic Treatment With Metformin and Oral Semaglutide vs. Metformin and Empagliflozin on Glycemic and Metabolic Control in Individuals With Short Duration Type 2 Diabetes","E-SEMPA","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes for up to 2 years (prior to randomization);\n* Aged between 18 and 70 years, both sexes, of any race or ethnicity;\n* HbA1c ≤8.0% at randomization;\n* Baseline treatment with metformin at a steady daily dose of ≥1500 mg;\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Treatment at any time in the past with SGLT2i, GLP-1RA, or DPP-4 inhibitors;\n* Insulin treatment for longer than 2 weeks in the past;\n* Body Mass Index below 22 kg\u002Fm2 or BMI above 40 kg\u002Fm2;\n* Chronic kidney disease stages 3-5 (eGFR below 60 ml\u002Fmin or the presence of albuminuria (urine albumin-to-creatinine ratio above 34 g\u002Fmmol);\n* Known cardiovascular disease (angina pectoris, history of myocardial infarction, ischemic heart disease, heart failure, known carotid atherosclerosis, objectively proven peripheral arterial disease, or other known atherosclerotic disease at other locations);\n* Moderate or severe liver disease (Child-Pugh stage B or C);\n* Personal history of pancreatitis;\n* Advanced heart failure (NYHA III-IV);\n* Retinopathy or maculopathy or their active treatment;\n* Pregnancy, expected pregnancy, or breastfeeding;\n* Presence of active malignancy or personal history of malignancy within 5 years of study enrollment;\n* Personal history of thyroid cancer; personal or family history of multiple endocrine neoplasia type 2 or family history of medullary thyroid carcinoma;\n* Chronic inflammatory bowel disease;\n* History of bariatric surgery or other gastrointestinal surgery that could affect drug or nutrient absorption;\n* Frequent or severe urinary tract infections;\n* Presence of a urinary catheter;\n* Troublesome and recurrent genital fungal infections;\n* Personal history of ketoacidosis;\n* Symptomatic hypotension or predisposition to hypovolemia;\n* History of organ transplantation;\n* Allergy to any component in the semaglutide or empagliflozin oral tablet;\n* Any medical or social circumstance that may limit participation in the study (e.g., inability to attend regular study visits);\n* Any other condition that, in the opinion of the principal and responsible investigators, may affect the safety or efficacy of the treatment.","70 Years",{"count":22,"type":23},[130],"The goal of this clinical trial is to learn if early combination with two antidiabetic drugs further improves blood glucose control compared to a single drug regimen in adults with short duration of type 2 diabetes. It will also learn about the effect of the combination treatment on body weight, body composition, blood lipids, oxidative stress, inflammation, metabolic control, insulin resistance and insulin secretion from pancreas, together with its safety profile. The main questions it aims to answer are:\n\n* Does early combination with two antidiabetic drugs improve blood glucose levels, determined by continuous glucose monitoring system?\n* Is early combination treatment as safe as treatment with a single antidiabetic drug?\n* Does early combination treatment reduces the need for rescue therapy?\n* Does early combination treatment reduces body weight and improves body composition?\n* Does early combination treatment improves blood lipid parameters, oxidative stress and inflammation?\n* Does early combination treatment improves metabolic parameters?\n* Does early combination treatment improves insulin resistance and insulin secretion?\n\nResearchers will compare early combination treatment with metformin and either peroral semaglutide or empagliflozin to a single drug regimen with only metformin to see if the combination treatment works to treat type 2 diabetes.\n\nParticipants will:\n\n* Take the combination of two antidiabetic drugs or only metformin for every day for 26 weeks.\n* Visit the clinic four times during the study duration for checkups and tests.\n* Carry a continuous glucose monitoring sensor for 14 days prior to study visits.",[389],"Type 2 Diabetes Mellitus (T2DM)",[382,391,137,392,136,393,394,395,396,397,398,399,400],"Early Combination Antihyperglycemic Treatment","Semaglutide","Glycemic Control","Metabolic Control","Type 2 Diabetes","Insulin Resistance","Time in Range","CGM","Continuous Glucose Monitoring","UMC Ljubljana","2026-04-29",{"date":403,"type":42},"2026-04-30",{"date":405,"type":42},"2024-10-01",{"date":407,"type":23},"2027-12",{"name":48,"class":49},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":417,"targetDuration":419,"studyType":24,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":50},"100517900","complicated-infections-in-otorhinolaryngology-100517900","NCT06023550","Complicated Infections in Otorhinolaryngology","Analysis of Complicated Infections in Pediatric and Adult Populations Treated by Otorhinolaryngologist","ENT_infect","Inclusion Criteria:\n\n* Diagnoses: rhinitis AND\u002FOR sinusitis AND\u002FOR facial cellulitis AND\u002FOR facial abscess AND\u002FOR nasal furuncle AND\u002FOR infection of the outer AND\u002FOR middle AND\u002FOR inner ear AND\u002FOR temporal bone AND\u002FOR infection of the soft tissues of the neck with\u002Fwithout bone and cartilage involvement AND\u002FOR laryngitis AND\u002FOR epiglottitis (or supraglottitis) AND\u002FOR\n* complication of inflammation of the nose and paranasal cavities AND\u002FOR ear AND\u002FOR temporal bone AND\u002FOR:\n* treated at the Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Center Ljubljana.\n\nExclusion Criteria:\n\n* disagreement of the patient and\u002For parents (or legal guardians) with inclusion in the research,\n* failure to meet the inclusion criteria.",{"count":418,"type":23},2550,"1 Year","This observational study aims to learn more about complicated infections treated by otorhinolaryngologists. The main questions to answer are:\n\n* What is the management of complicated sinonasal infections in Ljubljana, Slovenia,\n* What is the management of complicated ear and temporal bone infections in Ljubljana, Slovenia,\n* What is the management of complicated neck soft tissue infections in Ljubljana, Slovenia,\n* What is the management of complicated laryngeal infections in Ljubljana, Slovenia\n\nParticipants will receive standard treatment according to the established evidence-based clinical practice.",[422,423,424,425,426,427,428,429,430,431,432],"Sinusitis","Otitis","Laryngitis","Lymphadenitis","Quinsy","Peritonsillar Abscess","Parapharyngeal Abscess","Preseptal Cellulitis","Subperiosteal Abscess","Orbital Abscess","Epiglottitis","2026-04-27",{"date":401,"type":42},{"date":436,"type":42},"2024-09-01",{"date":438,"type":23},"2028-09",{"name":48,"class":49},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":448,"targetDuration":450,"studyType":24,"phases":4,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":50},"100485962","prospective-study-of-sinonasal-and-skull-base-tumours-management-100485962","NCT05607888","Prospective Study of Sinonasal and Skull-base Tumours Management","Prospective Observational Study of Sinonasal and Skull-base Tumours Management in a Tertiary Referral Otorhinolaryngology Service","Sinonasal_Tu","Inclusion Criteria:\n\n* sinonasal and\u002For skull-base cancer\n* sinonasal disease expanding through the skull-base\n* the patient's written informed consent\n\nExclusion Criteria:\n\n* lateral skull-base disease primarily originating in the temporal bone and without central skull-base involvement",{"count":449,"type":23},120,"5 Years","This observational prospective clinical study aims to describe the epidemiology, management and outcome of patients with sinonasal and skull-base pathology (tumours and diseases with malignant clinical characteristics) in a tertiary otorhinolaryngology referral centre. The main questions it aims to answer are:\n\n* what is the caseload of patients with the included pathology in our centre\n* what are the results of management of these cases\n* what are the epidemiological characteristics of included patients\n* what is the quality of life of included patients.",[453,454,455,456,457,458],"Nasal Neoplasm","Nasal Neoplasm Benign","Skull Base Neoplasms","Skull Base Osteomyelitis","Sinonasal Disorder","Sinus Disease",{"date":401,"type":42},{"date":461,"type":42},"2022-01-01",{"date":463,"type":23},"2027-12-31",{"name":48,"class":49},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":62,"phases":473,"briefSummary":474,"conditions":475,"keywords":477,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":50},"100321243","patients-pretreatment-expectations-about-post-lyme-symptoms-100321243","NCT03462329","Patient's Pretreatment Expectations About Post-Lyme Symptoms","Impact of Patient's Pretreatment Expectations on Treatment Outcome of Early Lyme Borreliosis","Inclusion Criteria:\n\n* erythema migrans\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* immunocompromised\n* taking antibiotic with antiborrelial activity within 10 days",{"count":362,"type":23},[64],"The investigators will focus on pretreatment expectations of patients with early Lyme disease manifested as erythema migrans with the aim of assessing the association between pretreatment expectations quantified with a questionnaire and treatment outcome quantified with the presence of post-Lyme symptoms. Furthermore, the investigators will compare the prevalence of nonspecific symptoms among patients and among age-matched controls without a history of Lyme borreliosis.",[476],"Erythema Migrans",[478,479],"Post-Lyme symptoms","Pretreatment expectations",{"date":401,"type":42},{"date":482,"type":42},"2018-06-01",{"date":484,"type":23},"2028-12-01",{"name":48,"class":49},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":62,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":50},"100311707","duration-of-doxycycline-treatment-in-mem-patients-100311707","NCT03337932","Duration of Doxycycline Treatment in MEM Patients","Duration of Doxycycline Treatment in Patients With Multiple Erythema Migrans (MEM). A Randomized Clinical Trial","Inclusion Criteria:\n\n• multiple erythema migrans\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* immunocompromised\n* serious adverse event to doxycycline\n* taking antibiotic with antiborrelial activity within 10 days\n* extracutaneous manifestations of lyme borreliosis",{"count":362,"type":23},[64],"The purpose of this study is to compare the efficacy of 7-day versus 14-day doxycycline treatment in patients with multiple erythema migrans.",[497],"Erythema Chronicum Migrans",{"date":401,"type":42},{"date":500,"type":42},"2018-05-01",{"date":463,"type":23},{"name":48,"class":49},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":511,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":62,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":50},"100601329","effect-of-immediate-skin-to-skin-contact-on-neonatal-heart-rate-variability-after-cesarean-secton-100601329","NCT07109076","Effect of Immediate Skin-to-Skin Contact on Neonatal Heart Rate Variability After Cesarean Secton","Effect of Immediate Skin-to-Skin Contact With the Mother on Heart Rate Variability in Newborns After Cesarean Secton","HRV-SCENE","Inclusion Criteria:\n\n* planned cesarean section\n* gestational age 39 weeks 0\u002F7 or more\n\nExclusion Criteria:\n\n* Pregnancy complications (e.g. hypertensive disorders in pregnancy, fetal growth restriction, etc.)\n* neonatal resuscitation at birth","0 Years",{"count":513,"type":23},80,[64],"At birth, both the newborn and the mother experience adaptive stress, which can be measured using objective physiological methods. One of the possible methods is monitoring heart rate variability, which is an indirect indicator of the balance between the sympathetic and parasympathetic branches of the autonomic nervous system. The proposed study will monitor the effect of early skin-to-skin contact on heart rate variability in newborns delivered by cesarean section and their mothers.\n\nThe researchers hypothesize that newborns and mothers who are provided with immediate direct skin-to-skin contact, compared to the control group receiving standard care, will exhibit higher heart beat-to-beat interval variability in the first hours after birth. This is expected to result from reduced stress and activation of the parasympathetic nervous system.\n\nThe study will include 80 newborn-mother pairs with a gestational age of 39 weeks or more, delivered via planned cesarean section. Participants will be randomly assigned to a study group (skin-to-skin contact lasting at least 15 minutes after cesarean birth) and a control group (standard care), with 40 newborns in each group. Maternal and neonatal ECG will be monitored for 15 minutes following cesarean birth in both groups. In addition, neonatal ECG will be monitored at 6, 12 and 24 hours postpartum. Time-domain analyses of hearth rate variability will be performed.",[517],"Neonatal Adaptation",[519,520,521,522],"heart rate variability","cesarean section","cesarean birth","skin-to-skin contact","2026-03-23",{"date":525,"type":42},"2026-03-27",{"date":527,"type":42},"2026-03-01",{"date":529,"type":23},"2026-12-02",{"name":48,"class":49},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":62,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":117},"100359893","phase-3-different-amoxicillin-treatment-regimens-in-erythema-migrans-patients-100359893","NCT03966014","Different Amoxicillin Treatment Regimens in Erythema Migrans Patients","Different Duration and Dosing of Amoxicillin in Patients With Erythema Migrans. A Randomized Clinical Trial.","Inclusion Criteria:\n\n* erythema migrans\n\nExclusion Criteria:\n\n* pregnancy\n* extracutaneous manifestations of Lyme borreliosis\n* immunocompromising state\n* serious adverse event to beta lactam antibiotic\n* receiving antibiotic with antiborrelial activity within 10 days",{"count":362,"type":23},[364],"The purpose of this study is to compare the efficacy of different amoxicilline treatment regimens in patients with erythema migrans.",[476],"2026-03-22",{"date":544,"type":42},"2026-03-25",{"date":546,"type":42},"2019-06-01",{"date":463,"type":23},{"name":48,"class":49},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":50},"100630309","orthostatic-and-postprandial-hypotension-in-hospitalized-older-adults-hope65-100630309","NCT07485998","Orthostatic And Postprandial Hypotension In Hospitalized Older Adults (HOPE65)","Orthostatic And Postprandial Hypotension In Hospitalized Older Adults: Prevalence And Association With Medications, Comorbidities, And Adverse Clinical Outcomes","HOPE65","Inclusion Criteria:\n\n* Age 65 years or older\n* Hospitalization in internal medicine departments at the University Medical Centre Ljubljana\n* Duration of hospitalization ≥48 hours\n* Hemodynamic stability confirmed by the treating physician\n* Ability to participate in study procedures\n* Ability to stand (with or without assistive devices for walking)\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Medical condition preventing study procedures (e.g., need for continuous supine position)\n* Inability to provide informed consent\n* Refusal to participate\n* Severe cognitive impairment or delirium\n* Acute critical illness requiring intensive treatment\n* Participation in another clinical study that could affect safety or study outcomes",{"count":558,"type":23},500,"The goal of this observational study is to determine how often orthostatic hypotension and postprandial hypotension occur in adults aged 65 years and older who are hospitalized in internal medicine departments.\n\nOrthostatic hypotension is defined as an excessive drop in blood pressure after standing up from a lying or sitting position. Postprandial hypotension is an excessive drop in blood pressure that occurs after eating a meal. These conditions can increase the risk of falls, fainting, loss of independence, and other health problems in older adults.\n\nThe main questions this study aims to answer are:\n\n* How common orthostatic hypotension and postprandial hypotension are in hospitalized adults aged 65 years and older.\n* Whether these conditions are associated with medication use, chronic diseases, and geriatric syndromes (such as frailty, cognitive impairment, and functional decline).\n\nParticipants will:\n\n* have blood pressure measured while lying down and standing\n* have blood pressure measured after a meal\n* undergo a comprehensive geriatric assessment, including evaluation of functional status, cognitive function, frailty, mobility, and nutritional status\n* provide information about medications and medical history\n* be followed for up to 12 months to record outcomes such as falls, syncope, hospitalization, and death",[561,562],"Orthostatic Hypotension","Postprandial Hypotension",[564,565,566,567,568,569,570],"Older Adults","Hospitalized Patients","Blood Pressure Regulation","Falls","Geriatric Syndromes","Comprehensive Geriatric Assessment","Antihypertensive Medication","2026-03-17",{"date":573,"type":42},"2026-03-20",{"date":575,"type":23},"2026-04",{"date":577,"type":23},"2030-06",{"name":48,"class":49},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":587,"conditions":588,"keywords":591,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":50},"100630037","autonomic-regulation-of-blood-pressure-and-heart-rate-during-orthostasis-and-exercise-in-healthy-and-hypertensive-individuals-100630037","NCT07482462","Autonomic Regulation of Blood Pressure and Heart Rate During Orthostasis and Exercise in Healthy and Hypertensive Individuals","Assessment of Autonomic Regulation of Blood Pressure and Heart Rate in Healthy and Hypertensive Individuals During Orthostasis and Physical Exercise","Inclusion Criteria:\n\n* Healthy volunteers aged 18-35 years without known acute or chronic disease, non-smokers, body mass index (BMI) 20-24.9 kg\u002Fm², and negative orthostatic test\n* Participants aged ≥60 years with arterial hypertension followed at the Department of Hypertension\n* Hypertension group: controlled arterial hypertension, negative orthostatic test, without diabetes mellitus\n* Hypertension with orthostatic hypotension group: controlled arterial hypertension and positive orthostatic test indicating orthostatic hypotension\n* Hypertension with orthostatic hypertension group: controlled arterial hypertension and positive orthostatic test indicating a rise in blood pressure during orthostatic testing\n* Hypertension with diabetes mellitus group: controlled arterial hypertension and diabetes mellitus without previously diagnosed autonomic dysfunction\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Dementia, neurodegenerative disease, or cognitive impairment preventing understanding of study procedures\n* Known cardiovascular disease including heart failure (NYHA II-IV), myocardial infarction within the previous 6 months, clinically significant arrhythmias, or peripheral arterial occlusive disease\n* Uncontrolled arterial hypertension\n* Change in antihypertensive therapy within the previous 4 weeks\n* Presence of a cardiac pacemaker\n* Treatment with antiarrhythmic drugs (class I, III, or IV), digoxin, alpha-receptor blockers, or other medications known to significantly affect heart rate variability or autonomic function\n* Advanced renal failure (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²) or advanced liver failure\n* Active malignancy\n* Body mass index ≥35 kg\u002Fm²\n* Acute illness within the previous 4 weeks\n* Current smoking\n* Inability to safely perform exercise testing on a cycle ergometer\n* Severe psychiatric disorders without stable treatment\n* Pregnancy or breastfeeding\n* Participation in another clinical study\n* Refusal or inability to provide written informed consent",{"count":449,"type":23},"The goal of this observational study is to assess arterial stiffness and autonomic regulation of blood pressure and heart rate in healthy adults and people with arterial hypertension during orthostatic stress and graded physical exercise. The main objective is to analyze cardiovascular responses to exercise on a cycle ergometer in different subgroups of participants with hypertension.\n\nThe study includes healthy young adults and older adults with hypertension. Participants undergo standardized assessments including orthostatic testing, graded exercise testing on a cycle ergometer, electrocardiography, and measurement of arterial stiffness parameters such as pulse wave velocity, as well as other vascular and hemodynamic parameters.\n\nThe results of this study are expected to improve understanding of cardiovascular physiology and autonomic regulation in people with hypertension and may contribute to earlier recognition of autonomic dysfunction and improved clinical management.",[589,590,561],"Hypertension","Autonomic Dysfunction",[592,593,594,595,596],"Orthostatic Test","Arterial Stiffness","Exercise Testing","Heart Rate Variability","Pulse Wave Velocity","2026-03-14",{"date":599,"type":42},"2026-03-19",{"date":601,"type":42},"2025-10-15",{"date":603,"type":23},"2027-03",{"name":48,"class":49},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":613,"conditions":614,"keywords":617,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":629,"locationsCount":4},"100628809","image-guided-central-catheter-insertion-with-concurrent-assessment-of-vascular-wall-integrity-100628809","NCT07466472","Image-Guided Central Catheter Insertion With Concurrent Assessment of Vascular Wall Integrity","Assessment of the Impact of a Peripherally Inserted Central Catheter on Vascular Wall Integrity","Inclusion Criteria:\n\n* sinus rhythm\n* medical indication\n* suitable upper-extremity venous anatomy confirmed by ultrasound examination\n* ability to provide written informed consent\n\nExclusion Criteria:\n\n* Implanted cardiac pacing device\n* Palliative care\n* \\\u003C18years old\n* Local infection, skin lesion, or burn at the intended insertion site\n* Severe coagulopathy contraindicating vascular access procedures\n* Known allergy to catheter materials or local anesthetics used during the procedure\n* Presenceof an implanted cardiac pacemaker or non-sinus cardiac rhythm preventing reliable intracavitary ECG guidance\n* Anatomical abnormalities preventing safe PICC insertion\n* Previous lymphadenectomy on the intended side\n* Pre-existing venous thrombosis or significant venous wall pathology detected on baseline ultrasound",{"count":513,"type":23},"The insertion of peripherally inserted central catheters (PICCs) represents a minimally invasive and safe method for establishing long-term central venous access in patients requiring prolonged intravenous therapy, including chemotherapy, parenteral nutrition, and long-term antibiotic treatment. Ultrasound-guided cannulation of peripheral arm veins improves procedural success, reduces complications, and increases patient comfort compared with centrally inserted central catheters.Accurate positioning of the catheter tip at the cavo-atrial junction is essential for optimal catheter function and safety. The Sherlock 3CG Tip Confirmation System combines electromagnetic tracking with intracavitary electrocardiography (ECG) to enable real-time catheter tip navigation and positioning.The aim of this prospective clinical study is to evaluate the accuracy and safety of ultrasound-guided PICC insertion using the Sherlock 3CG system, as well as to assess the impact of PICC placement on venous wall integrity. Ultrasound examination of the target vein will be performed before catheter insertion and after catheter removal to evaluate potential vascular wall changes associated with catheter use. A chest X-ray examination will be performed after each catheter insertion to confirm final catheter tip position and to assess the accuracy of the navigation system.Fluoroscopic guidance will be used only in selected cases, such as patients with anatomical anomalies, previously known difficult vascular access, or unsuccessful standard catheter advancement.A total of 80 adult patients with a clinical indication for PICC placement will be enrolled over a three-year study period.",[615,616],"PICC Line Placement","Vessels; Anomaly",[618,619,620,621,622],"PICC","Sherlock 3CG","Vessels Anomaly","Vessel Wall","Intracavitary Electrocardiogram","2026-03-09",{"date":625,"type":42},"2026-03-12",{"date":233,"type":23},{"date":628,"type":23},"2029-08-01",{"name":48,"class":49},{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":62,"phases":639,"briefSummary":640,"conditions":641,"keywords":644,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":662,"locationsCount":50},"100624154","phase-4-vericiguat-and-reverse-remodeling-indices-in-heart-failure-100624154","NCT07405944","Vericiguat and Reverse Remodeling Indices in Heart Failure","Vericiguat's Effects on Reverse Remodeling Indices: Pathophysiologic Approach to Treatment of Heart Failure With Reduced Ejection Fraction","VERI-PATH","Inclusion Criteria:\n\n* Written informed consent from an adult patient (≥ 18 years old) to participate in the clinical study,\n* Stable HFrEF defined as no heart failure worsening in the 6 months before randomization that required hospitalization or outpatient diuretic treatment,\n* Confirmed diagnosis of chronic heart failure with reduced ejection fraction (LVEF ≤ 40%, confirmed by echocardiography) within 12 months before randomization,\n* Stable GDMT for HFrEF for at least 3 months prior to randomisation.\n\nExclusion Criteria:\n\n* Systolic blood pressure \\\u003C 100 mmHg or symptomatic hypotension,\n* Current or planned use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type V inhibitors,\n* Known allergy\u002Fhypersensitivity to soluble guanylate cyclase stimulators,\n* Awaiting heart transplantation or dependence on continuous inotropic therapy\n* Cardiac amyloidosis, sarcoidosis, myocarditis, stress cardiomyopathy, or tachycardic cardiomyopathy,\n* Acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention in the past three months before randomisation,\n* Long-term mechanical circulatory support of the left ventricle,\n* Active infection,\n* Chronic kidney disease stage 4 or 5, and\n* Advanced liver failure classified as Child-Pugh B or C.",{"count":193,"type":23},[130],"The goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy.\n\nThe main questions are:\n\n* Does vericiguat improve right ventricular systolic function, measured by tricuspid annular plane systolic excursion (TAPSE)?\n* Does vericiguat favourably influence myocardial remodeling, fibrosis, angiogenesis, inflammation, metabolism, renal function, and hematologic balance?\n* Do genetic and oxidative stress profiles modify treatment response? Researchers will compare a group receiving vericiguat plus usual care with a group receiving usual care alone to assess structural, functional, and biomarker changes over 12 months.\n\nParticipants will:\n\n* Have blood drawn at baseline and follow-up visits for biomarker, metabolomic, genetic, transcriptomic, and hematologic analyses, including platelet function testing\n* Perform oral glucose tolerance tests (OGTT) to assess insulin resistance\n* Undergo echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy to evaluate heart structure, function, and perfusion\n* Attend follow-up visits at 1, 3, 6, and 12 months Open-label extension: After the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This exploratory extension will reassess study outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort.",[642,643],"Heart Failure With Reduced Ejection Fraction (HFrEF)","Chronic Heart Failure",[645,646,647,648,649,650,651,652,653,654,655,396],"Vericiguat","Soluble Guanylate Cyclase","Cyclic GMP","Reverse Remodeling","Cardiac Magnetic Resonance Imaging","Myocardial Perfusion Imaging","Fibrosis","Inflammation","Angiogenesis","Oxidative Stress","Immunomodulation","2026-02-08",{"date":658,"type":42},"2026-02-12",{"date":660,"type":42},"2025-11-01",{"date":463,"type":23},{"name":48,"class":49},{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":667,"acronym":4,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":156,"minAge":19,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":671,"conditions":672,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":4},"100622654","the-association-between-deep-endometriosis-and-the-occurrence-of-colorectal-carcinoma-100622654","NCT07386431","The Association Between Deep Endometriosis and the Occurrence of Colorectal Carcinoma","Inclusion Criteria:\n\nFemale patients aged 18 and over, treated at the Department of Reproduction for diagnosed deep endometriosis, including bowel endometriosis, for whom surgical treatment is indicated.\n\nExclusion Criteria:\n\n* Patients with known inflammatory bowel disease (IBD), patients with a personal history of gynecological or gastrointestinal malignancy",{"count":670,"type":23},30,"The goal of this study is to identify the molecular or genetic mechanisms that may predispose patients with bowel endometriosis to an increased risk of colorectal carcinoma. The study will include patients for whom surgical treatment of bowel endometriosis is clinically indicated.\n\nThis research would represent a significant advancement in evaluating the necessity of surgical intervention in asymptomatic patients or those with mild symptoms. Furthermore, it would provide a broader insight into the systemic impact of endometriosis on other organ systems, ultimately improving risk assessment and preventive measures.",[673,674,675,676,677,678,679,680,681,682],"Endometriosis","Deep Endometriosis","Bowel Endometriosis","Colorectal Carcinoma","Colon Resection","Endometriosis Pelvic","Endometriosis Rectum","Carcinogenesis","Genetic Change","Infertility","2026-02-05",{"date":685,"type":42},"2026-02-06",{"date":687,"type":23},"2026-02",{"date":689,"type":23},"2029-05",{"name":48,"class":49},{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":697,"eligibilityCriteria":698,"healthyVolunteers":12,"sex":156,"minAge":19,"maxAge":699,"enrollmentInfo":700,"targetDuration":4,"studyType":62,"phases":701,"briefSummary":702,"conditions":703,"keywords":705,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":715,"lastUpdatePostDateStruct":716,"startDateStruct":718,"completionDateStruct":720,"leadSponsor":721,"locationsCount":50},"100621685","tirzepatide-and-muscle-outcomes-in-obesity-100621685","NCT07373834","Tirzepatide and Muscle Outcomes in Obesity","Effects of Tirzepatide on Skeletal Muscle in Obesity","TIRMO","Inclusion Criteria:\n\n* Female sex\n* Age between 18 and 50 years\n* BMI between 30 kg\u002Fm² and 40 kg\u002Fm²\n* Stable body weight within the three months preceding study enrolment (defined as ≤ 5% change)\n* No prior pharmacological or surgical interventions for obesity treatment\n* Commitment to use barrier contraception and absence of plans for pregnancy within 8 months following enrolment\n\nExclusion Criteria:\n\n* Sarcopenic obesity\n* Pregnancy or lactation\n* Postmenopausal status\n* Diabetes\n* Immobility\n* Personal history of malignancy\n* Personal history of pancreatitis\n* Personal history of major depressive episodes\n* Personal history of myopathy\n* Personal or family history of medullary thyroid carcinoma\n* Current treatment with metformin or systemic corticosteroids","50 Years",{"count":670,"type":23},[64],"This study is evaluating whether a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, can affect the function, structure and metabolism of skeletal muscles in adults with obesity. Participants, premenopausal females with obesity, will receive either tirzepatide or placebo over 24 weeks. Researchers will assess body weight, body composition, muscle strength and functional performance, neuromuscular function and will perform muscle biopsies before and after treatment to study molecular and histological changes following treatment. The goal of this study is to investigate the effects of tirzepatide on skeletal muscle function, quantity, quality and metabolism in adults with obesity as well as clarify the molecular and structural adaptations in skeletal muscle during tirzepatide-induced weight loss, addressing an important gap in understanding the impact of incretin-based therapies on muscle health.",[704],"Obesity (Disorder)",[706,707,708,709,710,711,712,713,714],"Obesity","Tirzepatide","Skeletal muscle","Muscle quality","Muscle mass","Muscle strength","Muscle function","Myosteatosis","Muscle transcriptomics","2026-01-23",{"date":717,"type":42},"2026-01-28",{"date":719,"type":23},"2026-01",{"date":603,"type":23},{"name":48,"class":49},""]